Stay updated on Safety Tolerance Efficacy in IPF Clinical Trial

Sign up to get notified when there's something new on the Safety Tolerance Efficacy in IPF Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety Tolerance Efficacy in IPF Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a major change in the FGCL-3019-049 Protocol Amendment 3, offering a long-term extension of treatment with FG-3019 to eligible subjects with Idiopathic Pulmonary Fibrosis who completed specific assessments.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:08.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying age range, clinical diagnosis requirements, and other health conditions, replacing the previous lack of information on participation criteria.
    Difference
    25%
    Check dated 2024-05-22T21:00:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:37:16.000Z thumbnail image

Stay in the know with updates to Safety Tolerance Efficacy in IPF Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety Tolerance Efficacy in IPF Clinical Trial page.